Skip to main content

Primary Photoreceptor Disease

1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

BlueRock Therapeutics
BlueRock TherapeuticsGermany - Berlin
1 program
1
OpCT-001Phase 1/21 trial
Active Trials
NCT06789445Recruiting54Est. Oct 2030

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
2029
2030
BlueRock TherapeuticsOpCT-001

Clinical Trials (1)

Total enrollment: 54 patients across 1 trials

A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

Start: Mar 2025Est. completion: Oct 203054 patients
Phase 1/2Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 54 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.